Vicki L Keedy Selected Research

Neoplasms (Cancer)

3/2024	Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial.
12/2023	Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.
1/2022	Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
1/2022	Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
12/2021	Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors.
11/2021	Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas.
1/2020	Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors.
1/2020	Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study.
10/2018	First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors.
5/2018	The current landscape of early drug development for patients with sarcoma in the immunotherapy era.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vicki L Keedy Research Topics

Disease

24	Neoplasms (Cancer) 03/2024 - 12/2007
9	Sarcoma (Soft Tissue Sarcoma) 12/2023 - 01/2012
4	Synovial Sarcoma (Synovioma) 03/2024 - 08/2018
4	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 12/2023 - 02/2016
4	Neoplasm Metastasis (Metastasis) 03/2019 - 12/2007
3	Giant Cell Tumor of Tendon Sheath 04/2022 - 07/2015
3	Fibroma (Fibromatosis) 12/2012 - 09/2012
3	Aggressive Fibromatosis (Desmoid) 12/2012 - 09/2012
2	Myxoid Liposarcoma 03/2024 - 01/2022
2	Osteosarcoma (Osteogenic Sarcoma) 05/2023 - 10/2012
2	Carcinoma (Carcinomatosis) 01/2022 - 08/2009
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 02/2015
2	Chordoma 02/2016 - 04/2010
2	Giant Cell Tumors (Giant Cell Tumor) 07/2015 - 10/2012
2	Lung Neoplasms (Lung Cancer) 01/2013 - 05/2008
2	Cicatrix (Scar) 12/2012 - 10/2012
2	Leiomyosarcoma 11/2009 - 08/2009
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2009 - 12/2007
1	Hemoperitoneum 01/2023
1	Abdominal Pain (Pain, Abdominal) 01/2023
1	Edema (Dropsy) 04/2022
1	Triple Negative Breast Neoplasms 01/2022
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Thrombocytopenia (Thrombopenia) 01/2022
1	Nausea 01/2022
1	Prostatic Neoplasms (Prostate Cancer) 01/2022
1	Liposarcoma 11/2020
1	Brain Neoplasms (Brain Tumor) 03/2019
1	Neurofibrosarcoma (MPNST) 03/2019
1	Melanoma (Melanoma, Malignant) 05/2018
1	Febrile Neutropenia 11/2016
1	Alveolar Soft Part Sarcoma 02/2016
1	Dermatofibrosarcoma 02/2016
1	Pain (Aches) 01/2016
1	Inflammation (Inflammations) 01/2016
1	Body Weight (Weight, Body) 01/2015
1	Clinical Deterioration 06/2014
1	Disease Progression 03/2013

Drug/Important Bio-Agent (IBA)

4	Phosphotransferases (Kinase)IBA 12/2023 - 10/2012
3	Proteins (Proteins, Gene)FDA Link 12/2023 - 04/2010
3	pexidartinibIBA 04/2022 - 07/2015
3	Macrophage Colony-Stimulating FactorIBA 01/2022 - 07/2015
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022 - 04/2010
3	Irinotecan (Camptosar)FDA LinkGeneric 01/2015 - 11/2012
2	Estrogen ReceptorsIBA 01/2022 - 12/2012
2	Tyrosine Kinase InhibitorsIBA 01/2022 - 02/2016
2	ErbB Receptors (EGF Receptor)IBA 12/2021 - 10/2012
2	pazopanib FDA Link 11/2020 - 02/2016
2	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2020 - 12/2012
2	vactosertibIBA 01/2020 - 01/2020
2	Protein Isoforms (Isoforms)IBA 10/2012 - 04/2010
2	EnzymesIBA 04/2010 - 08/2009
1	HLA-A Antigens (HLA-A)IBA 03/2024
1	Ifosfamide FDA LinkGeneric 03/2024
1	AnthracyclinesIBA 03/2024
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 03/2024
1	TropomyosinIBA 12/2023
1	larotrectinibIBA 12/2023
1	tyramine-deoxysorbitolIBA 04/2022
1	Nuclear Proteins (Protein, Nuclear)IBA 01/2022
1	atezolizumabIBA 01/2022
1	molibresibIBA 01/2022
1	fms-Like Tyrosine Kinase 3IBA 01/2022
1	B7-H1 AntigenIBA 01/2022
1	seribantumabIBA 12/2021
1	Monoclonal AntibodiesIBA 12/2021
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 11/2021
1	olaparibIBA 11/2021
1	regorafenibIBA 11/2020
1	Transforming Growth Factor-beta Type I ReceptorIBA 01/2020
1	1- (3- (1- methyl- 1H- pyrazol- 4- yl)- 5- oxo- 5H- benzo(4,5)cyclohepta(1,2- b)pyridin- 7- yl)- N- (pyridin- 2- ylmethyl)methanesulfonamideIBA 10/2018
1	Gemcitabine FDA Link 08/2018
1	Docetaxel (Taxotere)FDA Link 08/2018
1	Immune Checkpoint InhibitorsIBA 05/2018
1	isophosphamide mustard (IPAM)IBA 11/2016
1	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2016
1	Sorafenib (BAY 43-9006)FDA Link 02/2016
1	cediranib (AZD2171)IBA 02/2016
1	Imatinib Mesylate (Gleevec)FDA Link 02/2016
1	Sunitinib (Sutent)FDA Link 02/2016
1	Albumin-Bound Paclitaxel FDA Link 02/2015
1	PlatinumIBA 02/2015
1	Carboplatin (JM8)FDA LinkGeneric 02/2015
1	Etoposide (VP 16)FDA LinkGeneric 02/2015
1	CateninsIBA 12/2012
1	Steroid Receptors (Steroid Receptor)IBA 12/2012
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 12/2012
1	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 12/2012

Therapy/Procedure

17	Therapeutics 03/2024 - 09/2006
10	Drug Therapy (Chemotherapy) 03/2024 - 09/2006
3	Radiotherapy 03/2019 - 11/2009
1	Neoadjuvant Therapy 01/2023
1	Castration 01/2022
1	Duration of Therapy 01/2022
1	Drug Tapering 01/2022
1	Particle Accelerators 03/2019
1	Aftercare (After-Treatment) 03/2019
1	Cell- and Tissue-Based Therapy (Cell Therapy) 05/2018
1	Immunotherapy 05/2018
1	Molecular Targeted Therapy 12/2012